The prochlorperazine maleate market is estimated to be valued at US$ 1.46 Bn in 2023 and is expected to exhibit a CAGR of 3.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Prochlorperazine maleate is an antipsychotic medication used primarily to control severe nausea and vomiting. It is commonly used to treat nausea and vomiting caused by conditions like motion sickness, vertigo, epilepsy, migraines, diabetes, surgery, cancer chemotherapy and labor. It works by blocking dopamine receptors in the brain. The drug is available in oral tablet, injection and suppository forms.

Market Dynamics:
The prochlorperazine maleate market is driven by increasing prevalence of nausea and vomiting related conditions globally. Nausea and vomiting is a common side effect associated with cancer chemotherapy. According to WHO, there were around 18.1 million new cases and 9.6 million cancer related deaths in 2018 globally. Additionally, the rise in cases of postoperative nausea and vomiting (PONV), especially due to growing number of surgeries is also expected to boost market growth during the forecast period. However, availability of alternative therapies for nausea and vomiting may hinder market growth. Additionally, side effects associated with prochlorperazine maleate like extrapyramidal symptoms including tremors and restlessness may also restrain the market growth.

SWOT Analysis

Strength: Prochlorperazine Maleate is an efficient antiemetic drug used to treat nausea and vomiting. It is an affordable option available as generic medication. It can be administered easily through oral and intravenous routes.

Weakness: Long term usage of Prochlorperazine Maleate can cause some serious side effects like movement disorders. It may also cause drowsiness and impair coordination in elderly patients.

Opportunity: Increasing number of cancer cases driving the need for antiemetic drugs for chemotherapy induced nausea and vomiting. Rising prevalence of gastrointestinal diseases presenting new market growth avenues.

Threats: Availability of alternative antiemetic drugs Like Ondansetron and Metoclopramide pose strong competition. Stringent regulatory approvals and compliance requirements for new drugs impact market profitability.

Key Takeaways

The global Prochlorperazine Maleate Market Size is expected to witness high growth, exhibiting CAGR of 3.5% over the forecast period, due to increasing prevalence of cancer and gastrointestinal diseases.

Regional analysis- North America dominates the global market holding over 35% share due to growing geriatric population suffering from vertigo and nausea. Asia Pacific shows fastest growth rate owing to rising healthcare investments and improving access to antiemetic treatments in countries like India and China.

Key players- Key players operating in the Prochlorperazine Maleate market are GlaxoSmithKline plc, Pfizer Inc., Novartis AG, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., Johnson & Johnson, AbbVie Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Lupin Limited.

Read More: https://www.dailyprbulletin.com/prochlorperazine-maleate-market-trends-growth-and-regional-outlook/